|
CH653021A5
(fr)
|
1981-04-24 |
1985-12-13 |
Delalande Sa |
Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
|
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
WO1990014844A2
(en)
|
1989-06-06 |
1990-12-13 |
Neorx Corporation |
Sugars as cleavable linkers for the delivery and release of agents in native form
|
|
US5650150A
(en)
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
ES2237750T3
(es)
*
|
1993-12-09 |
2005-08-01 |
Centro De Inmunologia Molecular |
Vacuna que comprende factor de crecimiento epidermico autologo humano y su uso.
|
|
JP4101302B2
(ja)
|
1997-01-09 |
2008-06-18 |
テルモ株式会社 |
新規アミド誘導体および合成中間体
|
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US20020155108A1
(en)
|
1998-05-04 |
2002-10-24 |
Biocrystal, Ltd. |
Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
|
|
US20090208418A1
(en)
*
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
|
FI107193B
(fi)
|
1999-06-03 |
2001-06-15 |
Rouvari Oy R |
Mittausanturi
|
|
SE9902036L
(sv)
|
1999-06-03 |
2000-07-31 |
Jan Folke Wallenius |
Förfarande och anordning för att under färd bestämma friktionen mellan vägbanan och ett fordons hjul
|
|
HK1041045A1
(zh)
|
1999-06-04 |
2002-06-28 |
蔡昌金 |
檢測抗滲的表面的裝置和方法
|
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
EP2264072A1
(en)
|
2000-04-13 |
2010-12-22 |
The Rockefeller University |
Enhancement of antibody-mediated cytotoxicity.
|
|
ATE440618T1
(de)
|
2000-06-22 |
2009-09-15 |
Univ Iowa Res Found |
Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
|
|
CA2418036A1
(en)
*
|
2000-07-31 |
2002-02-07 |
Yale University |
Innate immune system-directed vaccines
|
|
JP2004529102A
(ja)
|
2000-10-24 |
2004-09-24 |
イミュネックス・コーポレーション |
併用療法を用いて、腫瘍を治療する方法
|
|
CA2598144A1
(en)
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
|
CA2430206A1
(en)
|
2000-12-08 |
2002-06-13 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
|
US20040014779A1
(en)
|
2001-11-16 |
2004-01-22 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and toll-like recptor pathways
|
|
CA2467828C
(en)
|
2001-11-29 |
2011-10-04 |
3M Innovative Properties Company |
Pharmaceutical formulations comprising an immune response modifier
|
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
WO2003074566A2
(en)
|
2002-03-01 |
2003-09-12 |
Immunomedics, Inc. |
Rs7 antibodies
|
|
CN1671412B
(zh)
|
2002-08-15 |
2010-05-26 |
3M创新有限公司 |
免疫刺激组合物及刺激免疫反应的方法
|
|
US20040101909A1
(en)
|
2002-08-20 |
2004-05-27 |
Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 |
Purification of polyreactive autoantibodies and uses thereof
|
|
US6924154B2
(en)
|
2002-08-20 |
2005-08-02 |
Quest Diagnostics Investments Incorporated |
Hydrophilic chemilumescent acridinium labeling reagents
|
|
AU2003299082A1
(en)
|
2002-09-26 |
2004-04-19 |
3M Innovative Properties Company |
1h-imidazo dimers
|
|
AU2003287316A1
(en)
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
|
AU2003287324A1
(en)
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
|
US7091214B2
(en)
|
2002-12-20 |
2006-08-15 |
3M Innovative Properties Co. |
Aryl substituted Imidazoquinolines
|
|
WO2004060319A2
(en)
|
2002-12-30 |
2004-07-22 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
|
EP1592302A4
(en)
|
2003-02-13 |
2007-04-25 |
3M Innovative Properties Co |
METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
|
|
US7485432B2
(en)
|
2003-02-27 |
2009-02-03 |
3M Innovative Properties Company |
Selective modulation of TLR-mediated biological activity
|
|
US20040191833A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Selective activation of cellular activities mediated through a common toll-like receptor
|
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
|
US20040202720A1
(en)
|
2003-04-10 |
2004-10-14 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds using metal-containing particulate support materials
|
|
EP1617872A4
(en)
|
2003-04-10 |
2011-09-07 |
3M Innovative Properties Co |
METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE
|
|
US20040214851A1
(en)
|
2003-04-28 |
2004-10-28 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
MY157827A
(en)
|
2003-06-27 |
2016-07-29 |
3M Innovative Properties Co |
Sulfonamide substituted imidazoquinolines
|
|
JP2007501251A
(ja)
|
2003-08-05 |
2007-01-25 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調節剤化合物を使用する感染予防
|
|
US7799800B2
(en)
|
2003-08-14 |
2010-09-21 |
3M Innovative Properties Company |
Lipid-modified immune response modifiers
|
|
WO2005019429A2
(en)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
KR101106812B1
(ko)
|
2003-08-27 |
2012-01-19 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린
|
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
WO2005051324A2
(en)
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
|
WO2005065678A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Immunomodulatory combinations
|
|
US20060018911A1
(en)
|
2004-01-12 |
2006-01-26 |
Dana Ault-Riche |
Design of therapeutics and therapeutics
|
|
CA2559863A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
|
EP1735010A4
(en)
|
2004-04-09 |
2008-08-27 |
3M Innovative Properties Co |
METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
|
|
CN1997382A
(zh)
|
2004-05-05 |
2007-07-11 |
梅里麦克制药股份有限公司 |
调节生物活性的双特异性结合剂
|
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
|
US7884207B2
(en)
|
2004-06-18 |
2011-02-08 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
|
CN101065151B
(zh)
|
2004-09-23 |
2014-12-10 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
|
AU2005304771A1
(en)
|
2004-11-09 |
2006-05-18 |
University Of Southern California |
Targeted innate immunity
|
|
EP1814908A4
(en)
|
2004-11-22 |
2009-07-01 |
Biosight Ltd |
Activated labeling reagents and method for their preparation and use
|
|
US7943609B2
(en)
|
2004-12-30 |
2011-05-17 |
3M Innovative Proprerties Company |
Chiral fused [1,2]imidazo[4,5-C] ring compounds
|
|
WO2006073921A2
(en)
|
2004-12-30 |
2006-07-13 |
The Rockefeller University |
Compositions and methods for enhanced dendritic cell maturation and function
|
|
CA2597092A1
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
|
AU2006216997A1
(en)
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
|
EP2374451A3
(en)
|
2005-07-27 |
2012-01-25 |
University of Florida Research Foundation, Inc. |
Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
|
|
US8354249B2
(en)
|
2005-08-11 |
2013-01-15 |
Omrix Biopharmaceuticals Ltd. |
Intravenous immunoglobulin composition
|
|
CN101304748A
(zh)
|
2005-08-22 |
2008-11-12 |
加利福尼亚大学董事会 |
Tlr激动剂
|
|
US7700321B2
(en)
|
2005-10-21 |
2010-04-20 |
Genzyme Corporation |
Antibody-based therapeutics with enhanced ADCC activity
|
|
WO2007055916A2
(en)
|
2005-11-07 |
2007-05-18 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
|
WO2007100634A2
(en)
|
2006-02-22 |
2007-09-07 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
EP2589654A1
(en)
|
2006-05-03 |
2013-05-08 |
The Regents of the University of Colorado, a body corporate |
CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
JP2009542714A
(ja)
|
2006-06-30 |
2009-12-03 |
ベイラー リサーチ インスティテュート |
ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
|
|
GB0614098D0
(en)
|
2006-07-15 |
2006-08-23 |
Mnl Pharma Ltd |
Immune response variegation with imino sugars
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
US20080241139A1
(en)
|
2006-10-31 |
2008-10-02 |
Regents Of The University Of Colorado |
Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
|
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
|
AU2008218184B2
(en)
|
2007-02-02 |
2013-01-10 |
Baylor Research Institute |
Activation of human antigen-presenting cells through CLEC-6
|
|
JP2010519316A
(ja)
|
2007-02-23 |
2010-06-03 |
ベイラー リサーチ インスティテュート |
デクチン−１を介したヒト抗原提示細胞の活性化の治療への応用
|
|
DK2132229T3
(en)
|
2007-03-01 |
2016-06-20 |
Symphogen As |
Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
|
|
US8604172B2
(en)
|
2009-04-17 |
2013-12-10 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
|
JP2010530005A
(ja)
|
2007-06-15 |
2010-09-02 |
イミュアールエックス・インコーポレーテッド |
Ｔｎｆ−ｒアゴニスト療法レジメンの毒性を緩和するためのｔｌｒアゴニスト及び／又は１型インターフェロンの使用
|
|
KR20100063048A
(ko)
|
2007-07-31 |
2010-06-10 |
더 존스 홉킨스 유니버시티 |
신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체
|
|
WO2009059309A2
(en)
*
|
2007-11-01 |
2009-05-07 |
Panacea Pharmaceuticals, Inc. |
Furin-cleavable peptide linkers for drug-ligand conjugates
|
|
US20100098657A1
(en)
|
2007-12-27 |
2010-04-22 |
Schafer Peter H |
Method of Treating Cancer with Immunomodulatory Compounds and IgG
|
|
WO2009093250A2
(en)
|
2008-01-25 |
2009-07-30 |
Gavish-Galilee Bio Applications Ltd |
Targeting of innate immune response to tumor site
|
|
CA2720368C
(en)
|
2008-04-02 |
2017-08-22 |
Macrogenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
|
RU2503687C2
(ru)
|
2008-04-30 |
2014-01-10 |
Иммьюноджен, Инк. |
Сшивающие реагенты и их применение
|
|
JP2010032505A
(ja)
|
2008-06-30 |
2010-02-12 |
Arkray Inc |
目的物質の検出方法、それに用いる検出試薬およびその用途
|
|
CN102170907A
(zh)
|
2008-08-05 |
2011-08-31 |
东丽株式会社 |
用于治疗和预防癌症的药物组合物
|
|
US20100129383A1
(en)
|
2008-10-03 |
2010-05-27 |
The Governors Of The University Of Alberta |
Bifunctional fusion molecules for the delivery of antigens to professional antigen-presenting cells
|
|
US20100150942A1
(en)
|
2008-12-03 |
2010-06-17 |
Cantor Thomas L |
Affinity purified human polyclonal antibodies and methods of making and using them
|
|
WO2010132622A2
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
|
DK2467377T3
(en)
|
2009-08-18 |
2017-04-03 |
Ventirx Pharmaceuticals Inc |
SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
|
|
CN105669552A
(zh)
|
2009-08-18 |
2016-06-15 |
文蒂雷克斯药品公司 |
作为toll样受体调节剂的取代的苯并氮杂*
|
|
AU2010292172A1
(en)
|
2009-09-09 |
2012-05-03 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
|
GB0917054D0
(en)
|
2009-09-29 |
2009-11-11 |
Cytoguide As |
Agents, uses and methods
|
|
GB0917044D0
(en)
|
2009-09-29 |
2009-11-18 |
Cytoguide As |
Agents, uses and methods
|
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
|
CN102834113B
(zh)
|
2010-02-04 |
2016-03-02 |
东丽株式会社 |
癌的治疗和/或预防用药物组合物
|
|
CA2788718C
(en)
|
2010-02-04 |
2019-05-21 |
Shinichi Kobayashi |
Caprin-1 antibody for treating and/or preventing cancer
|
|
KR101801667B1
(ko)
|
2010-02-04 |
2017-11-27 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방용 의약 조성물
|
|
ES2543174T3
(es)
|
2010-02-04 |
2015-08-17 |
Toray Industries, Inc. |
Composición medicinal para el tratamiento y/o la prevención del cáncer
|
|
CA2788715C
(en)
|
2010-02-04 |
2021-06-08 |
Toray Industries, Inc. |
Pharmaceutical composition for treating and/or preventing cancer
|
|
US9203872B2
(en)
|
2010-02-19 |
2015-12-01 |
Microsoft Technology Licensing, Llc |
Distributed connectivity policy enforcement with ICE
|
|
GB201003293D0
(en)
|
2010-02-26 |
2010-04-14 |
Adjuvantix Ltd |
Cancer vaccine
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
US9169325B2
(en)
|
2010-04-13 |
2015-10-27 |
Celldex Therapeutics, Inc. |
Antibodies that bind human CD27 and uses thereof
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
RU2012152828A
(ru)
|
2010-05-07 |
2014-06-20 |
Бейлор Рисёч Инститьют |
Опосредованное иммунорецепторами дендритных клеток (dcir) перекрестное примирование cd8+ т клеток человека
|
|
SG185502A1
(en)
|
2010-05-14 |
2012-12-28 |
Abbvie Inc |
Il-1 binding proteins
|
|
CN119552249A
(zh)
|
2010-06-08 |
2025-03-04 |
基因泰克公司 |
半胱氨酸改造的抗体和偶联物
|
|
JPWO2011155579A1
(ja)
|
2010-06-10 |
2013-08-15 |
北海道公立大学法人 札幌医科大学 |
抗Ｔｒｏｐ−２抗体
|
|
EA201291482A1
(ru)
|
2010-07-09 |
2013-10-30 |
Байоджен Айдек Хемофилия Инк. |
Химерные факторы коагуляции
|
|
CA2804185C
(en)
|
2010-07-12 |
2017-03-21 |
Covx Technologies Ireland Limited |
Multifunctional antibody conjugates
|
|
RU2013110889A
(ru)
|
2010-08-13 |
2014-09-20 |
Бейлор Рисёч Инститьют |
Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
|
|
SG189071A1
(en)
|
2010-10-01 |
2013-05-31 |
Ventirx Pharmaceuticals Inc |
Therapeutic use of a tlr agonist and combination therapy
|
|
US20120321694A1
(en)
|
2010-10-27 |
2012-12-20 |
Daniel Larocque |
Compositions and uses
|
|
JP6014596B2
(ja)
|
2010-11-09 |
2016-10-25 |
メディミューン，エルエルシー |
均一コンジュゲーションのための抗体足場
|
|
US20120171229A1
(en)
|
2010-12-30 |
2012-07-05 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers with reactive groups that release biologically active agents
|
|
WO2012122396A1
(en)
|
2011-03-08 |
2012-09-13 |
Baylor Research Institute |
Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
|
|
EP2688592A4
(en)
|
2011-03-25 |
2015-07-22 |
Baylor Res Inst |
Compositions and methods for immunization against the hepatitis C virus
|
|
PT2699264T
(pt)
|
2011-04-20 |
2018-05-23 |
Medimmune Llc |
Anticorpos e outras moléculas que ligam b7-h1 e pd-1
|
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
|
WO2012166555A1
(en)
|
2011-05-27 |
2012-12-06 |
Nektar Therapeutics |
Water - soluble polymer - linked binding moiety and drug compounds
|
|
AU2012261959B2
(en)
|
2011-06-03 |
2015-12-03 |
Solventum Intellectual Properties Company |
Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
|
|
WO2012167088A1
(en)
|
2011-06-03 |
2012-12-06 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
|
WO2012170072A1
(en)
|
2011-06-06 |
2012-12-13 |
Immungene, Inc. |
Engineered antibody-tnfsf member ligand fusion molecules
|
|
US9180188B2
(en)
|
2011-08-04 |
2015-11-10 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prophylaxis of cancer
|
|
KR102041832B1
(ko)
|
2011-08-04 |
2019-11-08 |
도레이 카부시키가이샤 |
췌장암의 치료 및/또는 예방용 의약 조성물
|
|
JP6015448B2
(ja)
|
2011-08-04 |
2016-10-26 |
東レ株式会社 |
癌の治療及び／又は予防用医薬組成物
|
|
ES2609859T3
(es)
|
2011-08-04 |
2017-04-24 |
Toray Industries, Inc. |
Composición de fármaco para el tratamiento y/o la prevención del cáncer
|
|
EP2740794B1
(en)
|
2011-08-04 |
2018-04-04 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prophylaxis of cancer
|
|
EP2741085B1
(en)
|
2011-08-04 |
2017-04-05 |
Toray Industries, Inc. |
Method for detecting pancreatic cancer
|
|
PT2740796T
(pt)
|
2011-08-04 |
2017-07-26 |
Toray Industries |
Composição farmacêutica para o tratamento e/ou profilaxia de cancro
|
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
EP2756094B1
(en)
|
2011-08-15 |
2017-12-27 |
Medlmmune, LLC |
Anti-b7-h4 antibodies and their uses
|
|
US20140363461A1
(en)
|
2011-09-01 |
2014-12-11 |
Fabio Bagnoli |
Adjuvanted formulations of staphylococcus aureus antigens
|
|
WO2013043647A1
(en)
|
2011-09-19 |
2013-03-28 |
The Johns Hopkins University |
Cancer immunotherapy
|
|
NL2007536C2
(en)
|
2011-10-05 |
2013-04-08 |
Academisch Ziekenhuis Leiden Lumc |
Adjuvant compound.
|
|
US20130108619A1
(en)
|
2011-11-02 |
2013-05-02 |
Isaac Melamed |
Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods
|
|
CN104661683A
(zh)
|
2011-11-09 |
2015-05-27 |
埃森德生物制药有限公司 |
免疫调节缀合物
|
|
KR20140091040A
(ko)
|
2011-11-11 |
2014-07-18 |
리나트 뉴로사이언스 코프. |
Trop-2에 특이적인 항체 및 그의 용도
|
|
CA3111357A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
TW201341401A
(zh)
|
2012-01-09 |
2013-10-16 |
Covx Technologies Ireland Ltd |
突變抗體及其共軛
|
|
AU2013207927B2
(en)
|
2012-01-10 |
2017-11-02 |
Biogen Ma Inc. |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
|
EP2756093A4
(en)
|
2012-02-01 |
2015-07-01 |
Compugen Ltd |
C10RF32 ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
|
|
EP2818482B1
(en)
|
2012-02-21 |
2019-05-22 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment of cancer
|
|
MX357505B
(es)
|
2012-02-21 |
2018-07-12 |
Toray Industries |
Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
|
|
CN104114581B
(zh)
|
2012-02-21 |
2018-11-30 |
东丽株式会社 |
癌的治疗和/或预防用药物组合物
|
|
RU2633505C2
(ru)
|
2012-02-21 |
2017-10-12 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики рака
|
|
AU2013226090B2
(en)
|
2012-02-27 |
2018-03-08 |
Amunix Operating Inc. |
XTEN conjugate compositions and methods of making same
|
|
US9416193B2
(en)
|
2012-03-30 |
2016-08-16 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of liver cancer
|
|
RU2649802C2
(ru)
|
2012-03-30 |
2018-04-04 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
|
|
EP2836507A4
(en)
|
2012-04-13 |
2016-08-24 |
Whitehead Biomedical Inst |
SORTAS-MODIFIED VHH DOMAINS AND USES THEREOF
|
|
US9556167B2
(en)
|
2012-05-02 |
2017-01-31 |
Yale University |
TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
|
|
CN104470991A
(zh)
|
2012-05-30 |
2015-03-25 |
生命科技公司 |
荧光pH敏感性染料和其使用方法
|
|
EP2674170B1
(en)
|
2012-06-15 |
2014-11-19 |
Invivogen |
Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
|
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US20140065096A1
(en)
|
2012-09-05 |
2014-03-06 |
Regen BioPharma, Inc. |
Cancer therapy by ex vivo activated autologous immune cells
|
|
AU2014214751B2
(en)
|
2013-02-08 |
2017-06-01 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
EP2787005A1
(en)
|
2013-04-02 |
2014-10-08 |
Activartis Biotech GmbH |
Targeted cancer immune therapy
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
US20180104349A9
(en)
|
2013-04-28 |
2018-04-19 |
Gang Qin |
Novel linker, preparation method, and application thereof
|
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
|
AU2014303375B2
(en)
|
2013-08-09 |
2019-07-04 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
|
RU2016134258A
(ru)
|
2013-10-15 |
2018-02-28 |
Сорренто Терапьютикс Инк. |
Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами
|
|
GB201321242D0
(en)
|
2013-12-02 |
2014-01-15 |
Immune Targeting Systems Its Ltd |
Immunogenic compound
|
|
SG10201808519VA
(en)
|
2013-12-17 |
2018-10-30 |
Genentech Inc |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
|
EP3527587A1
(en)
|
2013-12-17 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
|
|
SI3424955T1
(sl)
|
2013-12-25 |
2025-08-29 |
Daiichi Sankyo Company, Limited |
Metoda za proizvodnjo konjugata protitelo-zdravilo anti-trop2
|
|
CN104861063A
(zh)
*
|
2014-01-10 |
2015-08-26 |
博笛生物科技有限公司 |
靶向her2阳性肿瘤的化合物和组合物
|
|
SG11201605296SA
(en)
|
2014-01-10 |
2016-07-28 |
Birdie Biopharmaceuticals Inc |
Compounds and compositions for treating her2 positive tumors
|
|
CN104861067A
(zh)
*
|
2014-01-10 |
2015-08-26 |
博笛生物科技有限公司 |
用于免疫疗法的化合物和组合物
|
|
EP3096787A4
(en)
|
2014-01-22 |
2018-02-07 |
The Board of Trustees of the Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
|
CN106456743A
(zh)
|
2014-02-21 |
2017-02-22 |
洛桑聚合联合学院 |
糖靶向性治疗剂
|
|
JP6357327B2
(ja)
|
2014-03-11 |
2018-07-11 |
株式会社クレハ |
フッ化ビニリデン系共重合体、その製造方法、ゲル電解質および非水系電池
|
|
WO2015138615A2
(en)
|
2014-03-12 |
2015-09-17 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
RS64072B1
(sr)
|
2014-03-19 |
2023-04-28 |
Genzyme Corp |
Mesto-specifični glikoinženjering ciljnih delova
|
|
DK3129406T3
(en)
|
2014-04-11 |
2019-04-01 |
Medimmune Llc |
CONJUGATED COMPOUNDS INCLUDING CYSTEIN MODIFIED ANTIBODIES
|
|
CA2938280C
(en)
|
2014-04-22 |
2022-07-12 |
F. Hoffmann-La Roche Ag |
4-amino-imidazoquinoline compounds
|
|
WO2015165413A1
(zh)
|
2014-04-29 |
2015-11-05 |
秦刚 |
一种新型的稳定型抗体药物耦联物及其制备方法和用途
|
|
JP2017521998A
(ja)
|
2014-05-12 |
2017-08-10 |
ヌマブ アクチェンゲゼルシャフト |
新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法
|
|
US10406198B2
(en)
|
2014-05-23 |
2019-09-10 |
Novartis Ag |
Methods for making conjugates from disulfide-containing proteins
|
|
CN106456736A
(zh)
|
2014-06-02 |
2017-02-22 |
贝勒研究院 |
用于治疗过敏和炎性疾病的方法和组合物
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
DK3166976T3
(da)
|
2014-07-09 |
2022-04-11 |
Birdie Biopharmaceuticals Inc |
Anti-pd-l1-kombinationer til behandling af tumorer
|
|
CN112546231A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
WO2016011401A1
(en)
|
2014-07-18 |
2016-01-21 |
Kedl Ross M |
Immunostimulatory combinations and use thereof
|
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
WO2016028149A1
(en)
|
2014-08-20 |
2016-02-25 |
Tu Eindhoven |
Ureidopyrimidone supramolecular complexes for compound delivery into cells
|
|
JP2017526673A
(ja)
*
|
2014-08-27 |
2017-09-14 |
国立大学法人九州大学 |
アジュバント
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
US9884866B2
(en)
|
2014-09-08 |
2018-02-06 |
Regents Of The University Of Minnesota |
Immunomodulators and immunomodulator conjugates
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US20170304433A1
(en)
|
2014-10-09 |
2017-10-26 |
Wake Forest University Health Sciences |
Vaccine compositions and methods of use to treat neonatal subjects
|
|
GB201418004D0
(en)
|
2014-10-10 |
2014-11-26 |
Isis Innovation |
Polymer adjuvant
|
|
EA201790834A1
(ru)
|
2014-10-14 |
2018-01-31 |
Новартис Аг |
Молекулы антител к pd-l1 и их применение
|
|
WO2016064749A2
(en)
|
2014-10-20 |
2016-04-28 |
Igenica Biotherapeutics, Inc. |
Novel antibody-drug conjugates and related compounds, compositions, and methods of use
|
|
WO2016064899A1
(en)
|
2014-10-21 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
|
ES2807182T3
(es)
|
2014-11-21 |
2021-02-22 |
Bristol Myers Squibb Co |
Anticuerpos frente a CD73 y sus usos
|
|
EP3223860A4
(en)
|
2014-11-25 |
2018-08-01 |
Endocyte, Inc. |
Methods of treating cancer by targeting tumor-associated macrophages
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
RS61470B1
(sr)
|
2014-12-31 |
2021-03-31 |
Checkmate Pharmaceuticals Inc |
Kombinovana antitumorska imunoterapija
|
|
CN107231804B
(zh)
|
2015-01-14 |
2019-11-26 |
百时美施贵宝公司 |
亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
|
|
WO2016112870A1
(en)
|
2015-01-16 |
2016-07-21 |
Tse-Wen Chang |
Molecular constructs with targeting and effector elements
|
|
ES2761861T3
(es)
|
2015-01-21 |
2020-05-21 |
Univ Leland Stanford Junior |
Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas
|
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
TWI703141B
(zh)
|
2015-03-12 |
2020-09-01 |
大陸商廣東東陽光藥業有限公司 |
作為丙型肝炎抑制劑的化合物及其在藥物中的應用
|
|
IL292449B2
(en)
|
2015-03-13 |
2024-02-01 |
Cytomx Therapeutics Inc |
Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
|
|
JP6815329B2
(ja)
|
2015-03-23 |
2021-01-20 |
バイエル ファーマ アクチエンゲゼルシャフト |
抗ｃｅａｃａｍ６抗体およびその使用
|
|
US20180117171A1
(en)
|
2015-04-01 |
2018-05-03 |
President And Fellows Of Harvard College |
Immunoconjugates for programming or reprogramming of cells
|
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
US10179817B2
(en)
|
2015-05-04 |
2019-01-15 |
Cytomx Therapeutics, Inc. |
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
|
|
ES2796698T3
(es)
|
2015-05-04 |
2020-11-30 |
Cytomx Therapeutics Inc |
Anticuerpos anti-CD166 activables y procedimientos de uso de los mismos
|
|
CN107922490A
(zh)
|
2015-05-04 |
2018-04-17 |
西托姆克斯治疗公司 |
抗ITGa3抗体、可活化抗ITGa3抗体及其使用方法
|
|
US20160324981A1
(en)
|
2015-05-08 |
2016-11-10 |
The California Institute For Biomedical Research |
Liver x receptor agonists and uses thereof
|
|
US10314854B2
(en)
|
2015-05-15 |
2019-06-11 |
University Of Iowa Foundation |
Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
|
|
TWI614023B
(zh)
|
2015-05-20 |
2018-02-11 |
免疫功坊股份有限公司 |
具有標的部分及效應部分的胜肽核多臂接合物
|
|
WO2016187656A1
(en)
|
2015-05-22 |
2016-12-01 |
La Trobe University |
Method of diagnosis of breast cancer
|
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
|
RS63897B1
(sr)
|
2015-05-29 |
2023-02-28 |
Bristol Myers Squibb Co |
Antitela protiv ox40 i njihova primena
|
|
US20180267024A1
(en)
|
2015-06-08 |
2018-09-20 |
Lophius Biosciences Gmbh |
Composition for determination of cell-mediated immune responsiveness
|
|
NZ737471A
(en)
|
2015-06-15 |
2022-02-25 |
Hangzhou Dac Biotech Co Ltd |
Hydrophilic linkers for conjugation
|
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
|
US10766962B2
(en)
|
2015-06-16 |
2020-09-08 |
The Regents Of The University Of California |
FZD7 specific antibodies and vaccines to treat cancer and control stem cell function
|
|
WO2016205566A1
(en)
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
CN113698335A
(zh)
|
2015-07-04 |
2021-11-26 |
杭州多禧生物科技有限公司 |
细胞结合分子的特异性偶联
|
|
WO2015151081A2
(en)
|
2015-07-12 |
2015-10-08 |
Suzhou M-Conj Biotech Co., Ltd |
Bridge linkers for conjugation of a cell-binding molecule
|
|
WO2017011580A2
(en)
|
2015-07-13 |
2017-01-19 |
Cytomx Therapeutics, Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
EP3328377A4
(en)
|
2015-07-31 |
2019-03-13 |
Tarveda Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
|
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
|
US20200079860A1
(en)
|
2015-08-06 |
2020-03-12 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for tumor therapy
|
|
CN115300640A
(zh)
|
2015-08-10 |
2022-11-08 |
杭州多禧生物科技有限公司 |
新型连接体及其用于药物和生物分子的特异性偶联
|
|
CA2996213C
(en)
|
2015-08-31 |
2023-10-03 |
3M Innovative Properties Company |
Guanidine substituted imidazo[4,5-c] ring compounds
|
|
JP6956071B2
(ja)
|
2015-08-31 |
2021-10-27 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換グアニジン基を含有するイミダゾ［４，５−ｃ］環状化合物
|
|
JP2018527350A
(ja)
|
2015-09-01 |
2018-09-20 |
イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． |
血餅形成の予防及び／又は血栓症の治療のための分子構築物
|
|
WO2017044803A1
(en)
|
2015-09-09 |
2017-03-16 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Service |
Expression vector delivery system and use thereof for inducing an immune response
|
|
KR102161364B1
(ko)
|
2015-09-14 |
2020-09-29 |
화이자 인코포레이티드 |
LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
|
|
WO2017053720A1
(en)
|
2015-09-25 |
2017-03-30 |
Tarveda Therapeutics, Inc. |
RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
|
|
EP3356371A4
(en)
|
2015-09-29 |
2020-06-24 |
The University of Chicago |
POLYMER CONJUGATE VACCINES
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
CA3003948A1
(en)
|
2015-11-02 |
2017-05-11 |
Ventirx Pharmaceuticals, Inc. |
Use of tlr8 agonists to treat cancer
|
|
US10988543B2
(en)
|
2015-11-11 |
2021-04-27 |
Opi Vi—Ip Holdco Llc |
Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
TWI703160B
(zh)
|
2015-11-30 |
2020-09-01 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
KR101795388B1
(ko)
|
2015-12-02 |
2017-11-09 |
현대자동차 주식회사 |
차량용 자동변속기의 유성기어트레인
|
|
US20170158772A1
(en)
|
2015-12-07 |
2017-06-08 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct - agonist conjugates and methods of use thereof
|
|
CA3007311A1
(en)
|
2015-12-07 |
2017-06-15 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct-agonist conjugates and methods of use thereof
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
US20190010236A1
(en)
|
2015-12-29 |
2019-01-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for dectin-2 stimulation and cancer immunotherapy
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CA3209672A1
(en)
|
2016-02-04 |
2016-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2017180834A1
(en)
|
2016-04-13 |
2017-10-19 |
Tarveda Therapeutics, Inc. |
Neurotensin receptor binding conjugates and formulations thereof
|
|
US10865244B2
(en)
|
2016-04-18 |
2020-12-15 |
Celldex Therapeutics, Inc. |
Nucleic acids encoding agonistic antibodies that bind CD40
|
|
US10533007B2
(en)
|
2016-04-19 |
2020-01-14 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
SG11201809082WA
(en)
|
2016-04-19 |
2018-11-29 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
|
PT3455257T
(pt)
|
2016-05-09 |
2021-12-06 |
Igm Biosciences Inc |
Anticorpos anti-pd-l1
|
|
TW201801751A
(zh)
|
2016-05-13 |
2018-01-16 |
塔維達治療公司 |
靶向構建體及其製劑
|
|
WO2017210246A2
(en)
|
2016-05-31 |
2017-12-07 |
Tarveda Therapeutics, Inc. |
Penicillamine conjugates and particles and formulations thereof
|
|
WO2017223085A2
(en)
|
2016-06-20 |
2017-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US10858483B2
(en)
|
2016-07-06 |
2020-12-08 |
University Of Maryland, College Park |
Polyphosphazene polyelectrolytes and uses thereof
|
|
CN109843327B
(zh)
|
2016-07-07 |
2022-05-13 |
小利兰·斯坦福大学托管委员会 |
抗体佐剂缀合物
|
|
BR112019004042A2
(pt)
|
2016-08-30 |
2019-05-28 |
Dana-Farber Cancer Institute, Inc. |
composições de liberação de fármaco e usos das mesmas
|
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
WO2018046460A1
(en)
|
2016-09-07 |
2018-03-15 |
Glaxosmithkline Biologicals S.A. |
Imidazoquinoline derivatives and their use in therapy
|
|
HRP20220144T1
(hr)
|
2016-09-09 |
2022-04-15 |
Novartis Ag |
Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora
|
|
WO2018078620A1
(en)
|
2016-10-25 |
2018-05-03 |
Urogen Pharma Ltd. |
Immunomodulating treatments of body cavities
|
|
JP7206590B2
(ja)
|
2016-10-28 |
2023-01-18 |
東レ株式会社 |
癌の治療及び／又は予防用医薬組成物
|
|
WO2018086139A1
(en)
|
2016-11-14 |
2018-05-17 |
Hangzhou Dac Biotech Co., Ltd |
Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
|
|
EP3554550A1
(en)
|
2016-12-13 |
2019-10-23 |
Bolt Biotherapeutics, Inc. |
Antibody adjuvant conjugates
|
|
JP2020500264A
(ja)
|
2016-12-15 |
2020-01-09 |
アーコニック インコーポレイテッドＡｒｃｏｎｉｃ Ｉｎｃ． |
耐食性アルミニウム合金
|
|
EP3559044A4
(en)
|
2016-12-23 |
2020-12-02 |
REMD Biotherapeutics, Inc. |
IMMUNOTHERAPY USING ANTIBODIES THAT BINDING PROGRAMMED CELL DEATH 1 (PD-1)
|
|
EP3559045A4
(en)
|
2016-12-23 |
2020-08-19 |
REMD Biotherapeutics, Inc. |
IMMUNOTHERAPY USING ANTIBODIES THAT BIND TO A TIMED DEATH LIGAND 1 (PD-L1)
|
|
KR102619747B1
(ko)
|
2017-01-10 |
2023-12-29 |
넥타르 테라퓨틱스 |
Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
|
|
CA3049791A1
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
EP3576782A4
(en)
|
2017-02-02 |
2020-12-30 |
Silverback Therapeutics, Inc. |
COMPOSITIONS OF RECOMBINATION PRODUCT-PEPTIDE AND THEIR METHODS OF USE
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
WO2018156617A2
(en)
|
2017-02-22 |
2018-08-30 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of polymer / biomacromolecule conjugates
|
|
KR20190125363A
(ko)
|
2017-03-06 |
2019-11-06 |
메르크 파텐트 게엠베하 |
수성 항-pd-l1 항체 제제
|
|
SG10202110182PA
(en)
|
2017-03-15 |
2021-10-28 |
Silverback Therapeutics Inc |
Benzazepine compounds, conjugates, and uses thereof
|
|
EP3595719A4
(en)
|
2017-03-16 |
2020-12-30 |
Immunwork Inc. |
LINKER UNITS AND MOLECULAR CONSTRUCTIONS WITH IT
|
|
WO2018175854A1
(en)
|
2017-03-23 |
2018-09-27 |
The Children's Medical Center Corporation |
Methods and compositions relating to adjuvants
|
|
RU2019134273A
(ru)
|
2017-03-31 |
2021-04-30 |
Займворкс Инк. |
Конструкты индуктора презентации антигена опухоли и их использование
|
|
CN110650750A
(zh)
|
2017-04-04 |
2020-01-03 |
阿维迪科技公司 |
基于肽的疫苗、其制造方法及其用于诱导免疫应答的用途
|
|
KR102739597B1
(ko)
|
2017-04-06 |
2024-12-06 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
비스-링키지를 사용한 세포독성 약물의 접합
|
|
US20180296685A1
(en)
|
2017-04-13 |
2018-10-18 |
Tarveda Therapeutics, Inc. |
Targeted constructs and formulations thereof
|
|
EP4218824A3
(en)
|
2017-04-14 |
2023-08-09 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate synthesis method
|
|
JP2020517256A
(ja)
|
2017-04-19 |
2020-06-18 |
エルスター セラピューティクス， インコーポレイテッド |
多重特異性分子およびその使用
|
|
CN118515666A
(zh)
|
2017-04-27 |
2024-08-20 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
EP3630148A4
(en)
|
2017-05-26 |
2021-06-16 |
The Johns Hopkins University |
MULTIFUNCTIONAL ANTIBODY LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE
|
|
EP3634401A1
(en)
|
2017-06-07 |
2020-04-15 |
Silverback Therapeutics, Inc. |
Antibody construct conjugates
|
|
EP3634485A4
(en)
|
2017-06-07 |
2021-07-21 |
Silverback Therapeutics, Inc. |
CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
|
|
US11517567B2
(en)
|
2017-06-23 |
2022-12-06 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
|
CA3067146A1
(en)
|
2017-06-28 |
2019-01-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for dectin-2 stimulation and cancer immunotherapy
|
|
WO2019023622A1
(en)
|
2017-07-27 |
2019-01-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
POLYMERIC NANOPARTICLES FOR IMPROVED ANTICANCERIC IMMUNOTHERAPY
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
|
US12030940B2
(en)
|
2017-08-17 |
2024-07-09 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
CN111511766B
(zh)
|
2017-10-13 |
2024-06-07 |
Ose免疫疗法 |
修饰的抗SIRPa抗体及其应用
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
EP3710059A1
(en)
|
2017-11-14 |
2020-09-23 |
Dynavax Technologies Corporation |
Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
|
|
CA3084667A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
JP7386161B2
(ja)
|
2017-12-19 |
2023-11-24 |
ブレイズ バイオサイエンス， インコーポレイテッド |
腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
|
|
CN112105646A
(zh)
|
2018-03-13 |
2020-12-18 |
Ose免疫疗法 |
抗人SIRPa v1抗体的用途和生产抗SIRPa v1抗体的方法
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2019195278A1
(en)
|
2018-04-02 |
2019-10-10 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
|
CN108379591B
(zh)
|
2018-04-03 |
2022-03-29 |
深圳大学 |
免疫激动剂靶向化合物的合成及其应用
|
|
US11485741B2
(en)
|
2018-04-24 |
2022-11-01 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (TLR7) agonists
|
|
ES3003787T3
(en)
|
2018-05-17 |
2025-03-11 |
Bolt Biotherapeutics Inc |
Immunoconjugates
|
|
KR20210016372A
(ko)
|
2018-06-04 |
2021-02-15 |
트러스티즈 오브 터프츠 칼리지 |
종양 미세환경-활성화된 약물-결합제 접합체, 및 이와 관련된 용도
|
|
CN114014932A
(zh)
|
2018-07-09 |
2022-02-08 |
启德医药科技（苏州）有限公司 |
滋养层细胞表面抗原2(trop2)特异性抗体
|
|
EP3827002A1
(en)
|
2018-07-24 |
2021-06-02 |
Torque Therapeutics, Inc. |
Tlr7/8 agonists and liposome compositions
|
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
|
US20210187115A1
(en)
|
2018-08-29 |
2021-06-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting EGFR
|
|
WO2020051356A1
(en)
|
2018-09-07 |
2020-03-12 |
Birdie Biopharmaceuticals, Inc. |
Imidazoquinoline compounds and uses thereof
|
|
US20200113912A1
(en)
|
2018-09-12 |
2020-04-16 |
Silverback Therapeutics, Inc. |
Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
|
|
WO2020056194A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Benzazepine compounds, conjugates, and uses thereof
|
|
JP2022500404A
(ja)
|
2018-09-12 |
2022-01-04 |
シルバーバック セラピューティックス インコーポレイテッド |
置換ベンゾアゼピン化合物、そのコンジュゲートおよび使用
|
|
US20220323596A1
(en)
|
2018-09-12 |
2022-10-13 |
Silverback Therapeutics, Inc. |
Antibody conjugates of toll-like receptor agonists
|
|
WO2020092617A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody conjugates comprising sting agonists
|
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
FI3886914T3
(fi)
|
2018-11-30 |
2023-05-26 |
Bristol Myers Squibb Co |
Glutamiinin sisältävän kevytketjun c-terminaalisen jatkeen käsittävä vasta-aine, sen konjugaatteja, ja menetelmiä ja käyttöjä
|
|
KR20210102334A
(ko)
|
2018-12-12 |
2021-08-19 |
브리스톨-마이어스 스큅 컴퍼니 |
트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도
|
|
KR20210130139A
(ko)
|
2018-12-26 |
2021-10-29 |
버디 바이오파마슈티칼즈, 인크. |
암 치료를 위한 면역 조절 조합 및 방법
|
|
US20220089768A1
(en)
|
2019-01-04 |
2022-03-24 |
Trio Pharmaceuticals, Inc. |
Multi-specific protein molecules and uses thereof
|
|
CA3125533A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma Oncology Division A/S |
Conjugates of pattern recognition receptor agonists
|
|
CN113660957B
(zh)
|
2019-02-12 |
2024-12-13 |
Ambrx公司 |
包含抗体-tlr激动剂缀合物的组合物、方法和用途
|
|
US20220143012A1
(en)
|
2019-03-15 |
2022-05-12 |
Bolt Biotherapeutics, Inc. |
Macromolecule-Supported TLR Agonists
|
|
US20220152215A1
(en)
|
2019-03-15 |
2022-05-19 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting CEA
|
|
WO2020190731A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
WO2020190734A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting pd-l1
|
|
AU2020241686A1
(en)
|
2019-03-15 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting HER2
|
|
EP3937939A4
(en)
|
2019-03-15 |
2022-12-07 |
Birdie Biopharmaceuticals Inc. |
IMMUNOMODULATORY COMBINATIONS AND METHODS OF TREATMENT OF CANCER
|
|
MX2021012035A
(es)
|
2019-04-05 |
2022-03-11 |
Dren Bio Inc |
Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos.
|
|
CN114206392A
(zh)
|
2019-06-10 |
2022-03-18 |
苏特罗生物制药公司 |
免疫调节剂抗体药物偶联物及其用途
|
|
TW202112752A
(zh)
|
2019-06-13 |
2021-04-01 |
美商博特生物治療公司 |
胺基苯并氮呯化合物、免疫接合物及其用途
|
|
JP7558205B2
(ja)
|
2019-06-13 |
2024-09-30 |
ボルト バイオセラピューティクス、インコーポレーテッド |
高分子支持アミノベンズアピン化合物
|
|
US20220259202A1
(en)
|
2019-06-17 |
2022-08-18 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
|
WO2020257407A1
(en)
|
2019-06-19 |
2020-12-24 |
Silverback Therapeutics, Inc. |
Anti-mesothelin antibodies and immunoconjugates thereof
|
|
US20210139477A1
(en)
|
2019-07-16 |
2021-05-13 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
|
BR112022001931A2
(pt)
|
2019-08-02 |
2022-06-21 |
Mersana Therapeutics Inc |
Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer
|
|
MX2022001719A
(es)
|
2019-08-15 |
2022-03-11 |
Silverback Therapeutics Inc |
Formulaciones de conjugados de benzazepina y usos de las mismas.
|
|
CN114630684A
(zh)
|
2019-09-03 |
2022-06-14 |
博尔特生物治疗药物有限公司 |
氨基喹啉化合物、免疫缀合物及其用途
|
|
US20220347312A1
(en)
|
2019-09-04 |
2022-11-03 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate Synthesis Method
|
|
JP2022548310A
(ja)
|
2019-09-23 |
2022-11-17 |
シートムエックス セラピューティクス，インコーポレイテッド |
抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
|
|
EP4037709A4
(en)
|
2019-09-30 |
2023-10-11 |
The Board of Trustees of the Leland Stanford Junior University |
KNOTTIN-IMMUNSTIMULANT CONJUGATES AND RELATED COMPOSITIONS AND METHODS
|
|
AU2020359446A1
(en)
|
2019-09-30 |
2022-04-21 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
WO2021072203A1
(en)
|
2019-10-09 |
2021-04-15 |
Silverback Therapeutics, Inc. |
Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof
|
|
MX2022004875A
(es)
|
2019-10-25 |
2022-06-17 |
Bolt Biotherapeutics Inc |
Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
|
|
JP2022554094A
(ja)
|
2019-10-25 |
2022-12-28 |
ボルト バイオセラピューティクス、インコーポレーテッド |
高分子支持チエノアゼピン化合物、及びそれらの使用
|
|
US20230074558A1
(en)
|
2019-12-06 |
2023-03-09 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
IL293926A
(en)
|
2019-12-17 |
2022-08-01 |
Pfizer |
Antibodies specific for cd47, pd-l1, and uses thereof
|
|
CN115175917A
(zh)
|
2019-12-31 |
2022-10-11 |
启德医药科技（苏州）有限公司 |
药物缀合物及其应用
|
|
WO2021136483A1
(en)
|
2019-12-31 |
2021-07-08 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
|
|
KR20220131301A
(ko)
|
2020-01-21 |
2022-09-27 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
항-pd-l1 항체
|
|
EP4093772A1
(en)
|
2020-01-21 |
2022-11-30 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1 antibodies
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
AU2021226570A1
(en)
|
2020-02-25 |
2022-09-29 |
Bolt Biotherapeutics, Inc. |
Cancer treatment methods
|
|
WO2021202921A1
(en)
|
2020-04-01 |
2021-10-07 |
Altimmune Uk Limited |
Imidazoquinoline-type compounds and uses thereof
|
|
US20230173093A1
(en)
|
2020-04-10 |
2023-06-08 |
Seagen Inc. |
Charge variant linkers
|
|
JP2023524092A
(ja)
|
2020-05-01 |
2023-06-08 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗デクチン－２抗体
|
|
CN115996756A
(zh)
|
2020-05-08 |
2023-04-21 |
博尔特生物治疗药物有限公司 |
弹性蛋白酶底物肽连接子免疫缀合物及其用途
|